Anne Wojcicki, the co-founder of the popular DNA testing company 23andMe, has successfully won a bid to regain control of the firm after it filed for bankruptcy earlier this year. Wojcicki’s nonprofit organization, TTAM Research Institute, outbid Regeneron Pharmaceuticals with a $305 million offer, securing the future of the company she helped create.
The bankruptcy filing in March was a result of declining demand for DNA testing services and the aftermath of a significant data breach in 2023 that had impacted the company’s reputation and customer trust. Despite these challenges, Wojcicki remained determined to rescue 23andMe and ensure its continued operation in the genetic testing market.
In a statement following the successful bid, 23andMe announced, “The agreement with non-profit TTAM Research Institute is the result of a final round of bidding that occurred earlier today between TTAM and Regeneron Pharmaceuticals.” This development signifies a significant milestone in the company’s journey towards recovery and revitalization under Wojcicki’s leadership.
The bidding process saw Wojcicki facing off against Regeneron Pharmaceuticals, a pharmaceutical giant that had initially offered $256 million to acquire 23andMe. In response to Regeneron’s bid, Wojcicki rallied support from a Fortune 500 company to bolster her own offer and secure the future of the genetic testing firm she co-founded.
The deal is now set to close in the coming weeks pending a court hearing scheduled for June 17, marking a new chapter in 23andMe’s story under Wojcicki’s renewed leadership. The outcome of this bid not only highlights Wojcicki’s commitment to the company’s mission but also underscores the importance of genetic testing and personalized medicine in today’s healthcare landscape.
With Wojcicki at the helm once again, 23andMe is poised to navigate the challenges ahead, rebuild customer trust, and continue its work in empowering individuals to explore their genetic heritage and make informed health decisions. As the company moves forward, the focus will be on leveraging cutting-edge technology, ethical practices, and transparency to deliver reliable genetic testing services to a global audience.
In conclusion, Anne Wojcicki’s successful bid to regain control of 23andMe represents a pivotal moment in the company’s history, signaling a new beginning and a renewed commitment to advancing genetic testing and personalized medicine in the years to come.
References:
1. https://science.slashdot.org/story/25/06/13/2046239/23andmes-founder-anne-wojcicki-wins-bid-for-dna-testing-firm?utm_source=rss1.0mainlinkanon&utm_medium=feed
2. https://www.theguardian.com/technology/2025/jun/16/23andme-founder-wins-bid-dna-testing
